Skip to main content
SpringerLink
Log in

Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model

  • Original Contributions
  • Published:
Diseases of the Colon & Rectum

Abstract

PURPOSE: In this study, we investigated the effect of the vitamin D 3 analog, EB1089, on the growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. METHODS: BALB/c Nu/Nu nude mice were inoculated subcutaneously with 10 6 LoVo cells. EB1089 dissolved in isopropanol was administered intraperitoneally and orally on alternate days at doses of 0.1, 0.5, and 2.5 μ g/kg/day. Control animals received isopropanol alone. Tumor volumes estimated using the formula 0.5×length×(width). The tumor kinetic index was determined by immunohistochemical detection of proliferating cell nuclear antigen. RESULTS: Significant dose-dependent inhibition of tumor growth was seen. After 20 days of treatment with 0.1 μ g/kg/day EB1089, mean tumor volume in treated mice was 41 to 49 percent less than that in control animals (P <0.01). Significant inhibition of tumor growth was also seen with 0.5 μ g/kg/day EB1089 after 22 days of treatment (51 percent of control P <0.01). Treatment with 2.5 μ g/kg/day resulted in weight loss that required termination of this group; these mice were subsequently found to be hypercalcemic. The tumor kinetic index was significantly lower in tumors treated with 0.1 μ g/kg/day EB1089 compared with that for control tumors (8 vs.30 percent in controls). CONCLUSION: These findings suggest that the vitamin D 3 analog, EB1089, is a potent antiproliferative agent for some human colon cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Chapter © 2017

Chapter © 2015

References

  1. Abe E, Miyaura C, Sakagami H,et al. Differentiation of mouse myeloid leukemia cells induced by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A 1981;76:4990–4.

    Google Scholar 

  2. Niendorf A, Arps H, Dietel M. Effect of 1,25-dihydroxyvitamin D3 on human cancer cellsin vitro. J Steriod Biochem 1987;27:825–8.

    Google Scholar 

  3. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer proliferation. Lancet 1989;1:188–91.

    PubMed  Google Scholar 

  4. Frampton RJ, Osmond SA, Eisman JA. Inhibition of human cancer cell growth by 1,25-Dihydroxyvitamin D3 metabolites. Cancer Res 1983;43:4443–7.

    PubMed  Google Scholar 

  5. Minghetti PP, Norman AW. 1,25-(OH)2-vitamin D3 receptor: gene regulation and genetic circuitry. FASEB J 1988;2:3043–53.

    PubMed  Google Scholar 

  6. Eisman JA, Barkla DH, Tutton PJ. Suppression ofin vivo growth of human cancer solid tumor xenograft by 1,25-Dihydroxyvitamin D3. Cancer Res 1987;47:21–5.

    PubMed  Google Scholar 

  7. Katsuyuki H, Shinomiya H. Novel vitamin D3 analogs and their potential for inhibiting cancer cell growth. Drugs Future 1993;18:1057–6l.

    Google Scholar 

  8. Colston KW, Mackay AG, James SY, Binderup I, Chander S, Coombes RC. EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cellsin vivo andin vitro. Biochem Pharmacol 1992;44:2273–80.

    PubMed  Google Scholar 

  9. Akhter J, Goerdel M, Morris DL. A vitamin D3 analogue (EB1089) inhibitsin vitro cellular proliferation of human colon cancer cells. Br J Surg 1996;83:229–30.

    PubMed  Google Scholar 

  10. Euhus D, Hudd C, La Regina M, Johnson F. Tumor measurement in nude mouse. J Surg Oncol 1986;31:229–34.

    PubMed  Google Scholar 

  11. Stewart GJ, Connor JL, Lawson JA, Preketes A, King J, Morris DL. Octreotide reduces the kinetic index, proliferating cell nuclear antigen-maximum proliferative index, in patients with colorectal cancer. Cancer 1995;76:572–8.

    PubMed  Google Scholar 

  12. Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E, Ikeda KA. Novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancerin vitro andin vivo without causing hypercalcemia. Endocrinology 1991;129:832–7.

    PubMed  Google Scholar 

  13. Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferationin vivo. Urology 1995;46:365–9.

    PubMed  Google Scholar 

  14. Shabahang M, Buras RR, Davoodi F, Scumaker IM, Nauta RJ, Evans DR. 1,25-Dihydroxyvitamine D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993;53:3712–8.

    PubMed  Google Scholar 

  15. Lointer P, Meggouh F, Dechelotte P,et al. 1,25-Dihydroxyvitamin D3 receptors and human colon adenocarcinoma. Br J Surg 1991;78:435–9.

    PubMed  Google Scholar 

  16. Frampton RJ, Suva J, Eisman JA,et al. Presence of 1,25-dihydroxyvitamin D3 receptors in established human cancer cell lines in culture. Cancer Res 1982;42:1116–9.

    PubMed  Google Scholar 

  17. Vandewalle B, Adenis A, Hornez I, Revillion F, Lefebvre J. 1,25-Dihydroxyvitamin D3 receptors in normal and malignant human colorectal tissues. Cancer Lett 1994;86:67–73.

    PubMed  Google Scholar 

  18. Lointier P, Wargovich MJ, Saez S, Levin B, Wildrick DM, Boman BM. The role of vitamin D3 in the proliferation of a human colon cancer cell linein vitro. Anticancer Res 1987;7:817–22.

    PubMed  Google Scholar 

  19. Eisman JA, Sutherland RL, McMenemy ML, Fragonas JC, Musgrove EA, Pang GY. Effects of 1,25-dihydroxyvitamin D3 on cell cycle kinetics of T47D human breast cancer cells. J Cell Physiol 1989;138:611–6.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, St. George Hospital, University of New South Wales, Sydney, Australia

    Javed Akhter M.Sc., Xianghai Chen M.D., Patricia Bowrey B.Sc., Elaine J. Bolton Ph.D. &  David L. Morris Ph.D.

Authors
  1. Javed Akhter M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xianghai Chen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia Bowrey B.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elaine J. Bolton Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David L. Morris Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

The human colonic adenocarcinoma cancer cell line, LoVo, was a gift from CRC Laboratories, Nottingham, United Kingdom.

Read at the Royal Australasian College of Surgeons Annual Scientific Congress, Melbourne, Australia, June 5 to 10, 1996.

About this article

Cite this article

Akhter, J., Chen, X., Bowrey, P. et al. Vitamin D3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis Colon Rectum 40, 317–321 (1997). https://doi.org/10.1007/BF02050422

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02050422

Key words

Search

Navigation